GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » Shiller PE Ratio
中文

Eterna Therapeutics (Eterna Therapeutics) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2021. Start your Free Trial

Eterna Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eterna Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Eterna Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
- - - -

Eterna Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Eterna Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eterna Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's Shiller PE Ratio falls into.



Eterna Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eterna Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Eterna Therapeutics  (NAS:ERNA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Eterna Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eterna Therapeutics (Eterna Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Executives
Dorothy J Clarke director C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder director C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft 10 percent owner 4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern 10 percent owner
Nicholas Jason Singer director 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore director 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson officer: Chief Financial Officer 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel officer: Interim President and CEO 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman director TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536

Eterna Therapeutics (Eterna Therapeutics) Headlines

From GuruFocus

Brooklyn ImmunoTherapeutics Announces Board Changes

By GuruFocusNews GuruFocusNews 06-07-2022